General Updates

SPIL/CS/SE/2026-2027/75 Date: 07th November 2026 The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 BSE Scrip Code: 543828 NSE Trading Symbol: SUDARSHAN Sub: Investor Presentation - Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ------------------------------------------------------------------------------------------------------- Dear Sir / Madam, In terms of Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor Presentation. Request you to take the same on your record. For, Sudarshan Pharma Industries Limited Hemal Vasantrai Mehta Chairman & Managing Director Encl: As above Regd. Off.: 301, Aura Biplex, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai – 400092. Sudarshan Pharma Industries Limited Innovating Chemistry, Empowering Health” INVESTOR PRESENTATION August 2026 E-mail :Compliance@sudarshanpharma.com Website:www.sudarshanpharma.com ContactNo:CS Niravshah:7700966328 COMPANY BACKGROUND & OVERVIEW SudarshanPharmaIndustriesLimited | Investor Presentation ASpecialty Chemicals & Pharmaceutical Trading and Manufacturing Company 18Years Founded in 2008, Sudarshan Pharma Industries Limited (SPIL) is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products DiversifiedProducts The Company specializes in host of products from rock chemicals intermediates and API to finish formulations and fully integrated pharmaceutical and chemicals GlobalReach The company has marked its presence in India and Internationalmarkets.Itsproductshavebeenexportedto the UK, Australia, Uzbekistan, Syria, Oman, Taiwan, andMENAregions. EsteemedClients Key clients in pharmaceutical formulations and specialty chemicals include Intas, Minova, Invision Life sciences, Omkar Pharma, SRF, Astral Pipes, DuPont,Reliance,BayerCorp,AkzoNobeletc SudarshanPharmaIndustriesLimited | Investor Presentation Milestones 2008- 2011- 2013- 2015- 2017- 2010 2012 2014 2016 2018 • 2008‐Expanded • Generic • Establishedour • Over5,000medical • Manufacturingof marketreachby formulations for footprintsin practitioners Nutraceuticals. importinghigh- institution supply, Gujarat,West associatedwith qualityraw NGOsand Bengal, SPIL. • BrandBrilliance materialsand wholesalemarket. Chhattisgarh,and AwardfromAsian products. UttarPradesh. • 7ownbranded Africanleadership • BrandedGeneric products foruminPharma. • 2009–Partnered formulationsin • Introducedbrands introduced withmanufacturers Maharashtra. inNewDrug successfullyin toscaleproduction DeliverySystem Vimac. andoptimizecosts. • 2010–Focusedon newproduct developmentand market-driven innovation. SudarshanPharmaIndustriesLimited | Investor Presentation Milestones 2019- 2021- 2023- 2024- 2025- 2020 2022 2024 2025 2026 • *Nutraceuticals • IVD-Section Got • New unit • Incorporated • Proposed Plant project cost 50Cr. Govt. Order. development in Sudarshan Maven Allotment of FCCB is Rs. 2.5 Cr. And • Successfully Palghar. Pharma Private of 20 Million USD Rs. 1.15 Cr • erected oral liquid • Listed on the BSE Limited • Acquired capex for Machinery cost. • and capsule SME Platform on • Acquired Ratna Rs. 25.50 Crores • *Launch Hart Kit manufacturing March 23, 2023. Lifesciences & 51% from Srigen Loading Dose And unit at Palghar. • Developing new of Ishwari Lifesciences Hart Kit4. • AATMA NIRBHAR products like Healthcare. Private Limited BHARAT Vitamin B1 and • Opened subsidiary • Manufacturing of Vitamin B6, which in Poland and USA Vitamin B1 & B6 will be the first • Migrated to the Under Production time made in India Main Board of BSE Linked Incentive by us. and listed on the Main Board of NSE (PLI) Schemes SudarshanPharama IndustriesLimited | Investor Presentation BusinessLayout ExistingBusinessLayout Thecompany isfocusingonincreasingmanufacturingcapabilitiesandhasstartedVerticalIntegrationforexpansioninthefollowingsegments: BrandedGenerics FinishedFormulation andF&OResearch& APIManufacturing Development andImport Intermediates forAPI ChemicalRaw Materialfor Pharmaceuticals Pharmabeginswith Asanorganizationbuiltontheprinciplesofupwardintegrationwithinthepharmaceuticalindustry,wearecommitted todeliveringhigh-qualityproductsat affordablepriceswhileconsistentlyinvestinginin-houseR&D. SudarshanPharmaIndustriesLimited | Investor Presentation Subsidiaries SUDARSHANPHARMAINDUSTRIES LTD. Wholly Owned Subsidiaries 51% Ownership Ratna Lifescience Pvt. Ltd. Life Science Chemical Sudarshan Industries Ishwari Healthcare Pvt. Ltd. Pvt. Ltd. INC, USA ((now divested) Existing Products: Existing Products: ExistingProducts: •Gemcitabine • Tannin extracts • Pharmaceuticals • PolyglycolicAcidSutures Hydrochloride • Solvents • Antibiotics • Polypropylene Mesh •2,2-difluoro-2 – • Dyestuffs • Drugs, • Infant FeedingTube •deoxycytidine-3, • Pigments • Medicines, • ThoracicDrainageCatheter 5-dibenzoate (T9) • Biological, •ImatinibMesylate • Neutraceuticals, •Capecitabine • Ayurvedic Intermediate (Cap-5) • Dietary SudarshanPharmaIndustriesLimited | Investor Presentation Subsidiaries SUDARSHANPHARMAINDUSTRIES LTD. Wholly Owned Subsidiaries 70% Ownership Sudarshan Pharma Cibachem General Trading Sudarshan Maven SudarshanPharma Industries Private Limited, LLC, Dubai Pharma Private Limited LifesciencePrivate Singapore Limited Trading activities of all Existing Products: The Company is engaged types of goods and in wholesale trading • Pharmaceuticals, Existing Products: ancillary insurance activities across various • API & Intermediates, • Pharmaceuticals activities categories, including • Antibiotics,Drugs, • Antibiotics, Drugs, basic industrial chemicals. Medicines, Medicines • Biological • Biological Products neutraceuticals. SudarshanPharmaIndustriesLimited | Investor Presentation Key Products SPEKeCyIAPLroIdTuYcGtsREEN CHEMICALS Acetonitrile Tetrahydrofuran(THF) 1, 4-Dioxane DMF/DMSO NMP(N-Methyl-2- Meta xylene N-Heptane Diethanolamine pyrrolidone) PHARMADIVISION Outof96products,56areregisteredunderthe“R”Trade Mark. • SPILhas introducedanoveldrugdeliverysystemundertheLoveBird“R”Brand,featuringa mouth-dissolvingstripwith5productsinthiscategory. • ForthefirsttimeinIndia,SPILhaslaunchedspecialtyproductsinthecardiacsegment,includingthe HARTKITLD, whichprovideslife-savingdrugsfor firstaidinheartattacks. • Theproduct“SETDOWN”,introducedforthefirsttimeinIndia,combinesallopathyandayurvedatoenablefasterrecoveryfromconstipation. • Top-SellingBrandsintheIndianMarketinclude:METFOCAL,PULMORELIEFAX,RDMACDSR,SETDOWN,ENAMOLSPHemD3,JIVANKIT (ImmunityBooster),and InfortQ-10,amongothers. SudarshanPharmaIndustriesLimited | Investor Presentation Key Products PERFORMANCE CHEMICALS & INTERMEDIATE CAMPAIGN BASIS • Specialize Performance Chemials • Sesamol (3,4-(Methylenedioxy)phenol) CAS. 533-31-3 (Having Patent Filled on April 16th 2026). • 4-((4-Fluorophenyl)imino)methyl)phenol CAS. 3382-63-6 • (S)-3-[5-(4-Fluorophenyl)-1,5-dioxopentyl]-4-phenyloxazolidin-2-one CAS. 189028-93-1 • (S)-3-((2R,5S)-5-(4-Fluorophenyl)-2-((S)-((4-fluorophenyl)amino)(4-((trimethylsilyl)oxy)phenyl)methyl)-5- ((trimethylsilyl)oxy)pentanoyl)-4-phenyloxazolidin-2-one CAS. 272778-12-8 • Meldrumsacid CAS. 2033-24-1 • 4-Nitro benzene sulfonyl chloride CAS. 98-74-8 • CIS LACTUM CAS. 189028-93-1 • 2,2-Dimethyl-1,2-dimethyl-4,6-dione CAS.2033-24-1 • 3-Morpholino-2-cyanoacrylamide CAS. 25229-97-4 • 3-Aminopyrazole-4-carboxamide Hemisulphate CAS. 27511-79-1 • 4-(chlorosulfonyl)benzoic acid CAS. 10130-89-9 • Piperidine-2-carbonyl chloride Hydrochloride CAS. 98626-58-5 • N-(2,6-dimethylphenyl) piperidine-2-carxamide hydrochloride CAS. 65797-42-4 • 1-Butyl-N-(2,6-dimethylphenyl) piperidine-2-carboxamide CAS. 27262-48-2 • (S)-piperidine-2-carbo [Showing first 8,000 characters — download PDF for full document]